Sage Alums Launch Tortugas with $106 Million in Funding

Jeff Jonas and Al Robichaud, former leaders at Sage Therapeutics, have officially launched Tortugas Neuroscience, a new biotech company. The launch was accompanied by a $106 million funding round led by Cure Ventures, with participation from Column Group, among others. While the field of neurological disorders carries inherent risks due to high clinical failure rates, the experienced founding team and substantial capital injection have enabled Tortugas to establish a solid foundation for research and development from an early stage.

Global Pipeline of Validated Small Molecule Assets

Tortugas has in-licensed four small molecule assets that are already in clinical development from Hansoh Pharma in China and Eisai in Japan. These include TRTL-107 (a D2/D3 partial agonist and 5-HT2A antagonist) for schizophrenia from Hansoh, and TRTL-913 (a GABA-A PAM) for tinnitus, also from Hansoh. From Eisai, Tortugas has acquired TRTL-729 (a GAT-1 inhibitor) for focal epilepsy and TRTL-118, a PDE9 inhibitor, to rapidly build its central nervous system (CNS) portfolio.

Targeting Large and Unmet Needs in Neurological Disorders

The market for schizophrenia treatments is projected to reach $7.8 billion to $9.5 billion globally by 2026, and the epilepsy market is also substantial, at approximately $12 billion, representing significant growth potential. Tinnitus, which affects hundreds of millions of people worldwide, is a particularly underserved area, with no currently approved, disease-modifying drugs. Tortugas' pipeline consists of orally administered drugs designed for improved patient convenience, offering the potential to transform the treatment paradigm if successfully developed.

Accelerating Phase 2 Trials and Managing Risk with Lessons from Sage

The newly secured funding will be primarily used to complete Phase 2 trials for key pipeline assets and support the advancement of subsequent candidates into clinical development. Management has outlined a plan to release initial clinical data for key candidates by the end of 2026, demonstrating a commitment to rapid development. This strategy reflects a proactive approach to risk management, leveraging lessons learned from past clinical delays and commercialization challenges at Sage, by focusing on validated, in-licensed assets rather than early-stage discovery programs.

A Novel Business Model for Biotech: Cross-Border Collaboration

This launch exemplifies a modern biotech business model, where a Western startup secures a pipeline from an Asian pharmaceutical company to maximize value. The increased activity in cross-border licensing deals creates significant career opportunities in areas such as cross-border clinical development and project management for industry professionals and job seekers. Ultimately, this model, which prioritizes rapid advancement of clinical-stage assets, is poised to become a core strategy within the industry.